Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
SGLT2 inhibitors
sulphonylureas (SUs)
Probably lowered increases in HbA1c over time−0.28
randomisedthe abstract, start to end
… weeks to 96-104 weeks, the pooled MD was -0.28% (95% CI: -0.35 to -0.20; p < …
… 48-52 weeks to 96-104 weeks, the MD was -0.11% (95% CI: -0.19 to -0.04; p = …
… and from 104 weeks to 208 weeks (MD: -0.12%; 95% CI: -0.25 to -0.01; p = …
← favours treatmentfavours comparator →
could be chanceIncreases in HbA1c over timeSGLT2 inhibitors vs sulphonylureas (SUs)
−0.28−0.35 to −0.20
Increases in HbA1c over timeSGLT2 inhibitors vs sulphonylureas (SUs)
−0.11−0.19 to −0.04
Increases in HbA1c over timeSGLT2 inhibitors vs sulphonylureas (SUs)
−0.12−0.25 to −0.01
SGLT2 inhibitorsGlycemic control
1 / 4